CHEMOTHERAPY-INDUCED METABOLIC STRESS IN IDH1 MUTANT GLIOMAS

被引：0
|
作者：
Tateishi, Kensuke [1 ]
Wakimoto, Hiroaki [2 ,3 ]
Higuchi, Fumi [1 ]
Miller, Julie [1 ]
Koerner, Mara V. A. [1 ]
Lelic, Nina [1 ]
Shankar, Ganesh [1 ]
Tanaka, Shota [1 ]
Curry, William T. [1 ]
Fisher, David E. [1 ]
Batchelor, Tracy T. [1 ]
Iafrate, A. John [1 ]
Chi, Andrew S. [4 ]
Cahill, Daniel P. [1 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA
[3] Harvard Med Sch, Boston, MA USA
[4] NYU, Langone Med Ctr, New York, NY USA
来源：
NEURO-ONCOLOGY | 2016年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EXTH-37
引用
收藏
页码：67 / 67
页数：1
相关论文
共 50 条
  • [41] IDH1 Overexpression Induced Chemotherapy Resistance and IDH1 Mutation Enhanced Chemotherapy Sensitivity in Glioma Cells in Vitro and in Vivo
    Wang, Ju-Bo
    Dong, Dan-Feng
    Wang, Mao-De
    Gao, Ke
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (01) : 427 - 432
  • [42] Mutant IDH1 is required for IDH1 mutated tumor cell growth
    Jin, Genglin
    Pirozzi, Christopher J.
    Chen, Lee H.
    Lopez, Giselle Y.
    Duncan, Christopher G.
    Feng, Jie
    Spasojevic, Ivan
    Bigner, Darell D.
    He, Yiping
    Yan, Hai
    ONCOTARGET, 2012, 3 (08) : 774 - 782
  • [43] Metabolic analysis of IDH mutant gliomas in Drosophila
    Brown, Michaela
    Buccetti, Jenna
    Tipping, Marla
    CANCER RESEARCH, 2016, 76
  • [44] Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas.
    Natsume, Atsushi
    Wakabayashi, Toshihiko
    Miyakita, Yasuji
    Narita, Yoshitaka
    Mineharu, Yohei
    Arakawa, Yoshiki
    Yamasaki, Fumiyuki
    Sugiyama, Kazuhiko
    Hata, Nobuhiro
    Muragaki, Yoshihiro
    Nishikawa, Ryo
    Shinojima, Naoki
    Kumabe, Toshihiro
    Saito, Ryuta
    Ito, Kazumi
    Tachibana, Masaya
    Kakurai, Yasuyuki
    Nishijima, Soichiro
    Tsubouchi, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] IDH1 AND IDH2 MUTATIONS AND THEIR CORRELATIONS IN GLIOMAS
    Mellai, M.
    Monzeglio, O.
    Piazzi, A.
    Giordano, M.
    Andreoli, E.
    Cassoni, P.
    Schiffer, D.
    NEURO-ONCOLOGY, 2010, 12 : 32 - 32
  • [46] Targeting IDH1/IDH2 mutations in gliomas
    de la Fuente, Macarena I.
    CURRENT OPINION IN NEUROLOGY, 2022, 35 (06) : 787 - 793
  • [47] Inhibitors of mutant IDH1 and IDH2
    Pamela Feliciano
    Nature Genetics, 2013, 45 (5) : 477 - 477
  • [48] IDH1 and IDH2 Mutations in Gliomas REPLY
    Reitman, Zachary
    Yan, Hai
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (21): : 2249 - 2249
  • [49] CHARACTERIZATION OF DIFFERENTIAL 5-HYDROXYMETHYLCYTOSINE IN IDH1 MUTANT VERSUS IDH1 WILD-TYPE HIGH-GRADE GLIOMAS
    Glowacka, Wioletta
    Jain, Harshika
    Okura, Makiko
    Maimaitiming, Abulizi
    Yasin, Mamatjan
    Farooq, Hamza
    Aldape, Kenneth
    Kongkham, Paul
    NEURO-ONCOLOGY, 2017, 19 : 95 - 95
  • [50] Increased Frequency of Presenting with Seizures in Patients with Isocitrate Dehydrogenase 1 (IDH1) Mutant Gliomas
    Chou, Arthur Po-Fei
    Ching, Harry
    Chang, Stephen
    Carrillo, Jose
    Lalezari, Shadi
    Spasic, Marko
    Choy, Winward
    Kim, Andrew
    Selfridge, Julia
    Quan, Jennifer
    Philippou, Yiannis
    Dye, Justin
    Soto, Horacio
    Nagasawa, Daniel
    Mathern, Gary
    Green, Richard
    Yang, Issac
    Prins, Robert
    Lai, Albert
    Liau, Linda
    JOURNAL OF NEUROSURGERY, 2012, 117 (02) : A440 - A440
12345